Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Deal With BI, Lilly Gets Late-Stage Diabetes Drugs

Executive Summary

Eli Lilly & Co., on the precipice of one of the steepest patent cliffs in the industry, announced a diabetes collaboration with Boehringer Ingehheim GmbH Jan. 11 that will recharge the company's diabetes pipeline but may leave investors longing for bigger M&A action.

Related Content

Boehringer’s Trajenta Enters China As DPP-4 Latecomer, But Playing Field Still Level
Bristol And AstraZeneca Make A Splash In Diabetes With Joint Purchase Of Amylin
J&J’s Canagliflozin Positive Phase III Data In The Limelight At ADA
Dapagliflozin Faces Ominous Prospect Of New Trials
Boehringer/Lilly's Linagliptin Approved: Can Renal Flexibility Unlock The DPP-4 Market?
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2011
Boehringer Ingelheim Plays Catch-Up In Diabetes, Close To Filing DPP-4 Drug
Forest Ends Phenomix Partnership, But Says Its Many Deals Are Bearing Fruit
Boehringer Ingelheim: Privacy Has its Virtues
Boehringer Ingelheim: Privacy Has its Virtues





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts